

Europäisches Patentamt  
European Patent Office  
Office européen des brevets



(11)

EP 0 365 657 B1

(12)

# EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention  
of the grant of the patent:  
04.08.1999 Bulletin 1999/31

(51) Int Cl.<sup>6</sup>: **C07K 14/435**, C07K 14/72,  
C07H 17/02, C12N 15/00

(21) Application number: 89905317.7

(86) International application number:  
PCT/US89/01548

(22) Date of filing: 13.04.1989

(87) International publication number:  
WO 89/09791 (19.10.1989 Gazette 1989/25)

(54) **DNA ENCODING ANDROGEN RECEPTOR PROTEIN**

FÜR ANDROGEN-REZEPTOR-PROTEIN KODIERENDE DNA

ADN CODANT POUR DES PROTEINES RECEPTRICES D'ANDROGENE

(84) Designated Contracting States:  
AT BE CH DE FR GB IT LI LU NL SE

(30) Priority: 14.04.1988 US 182646

(43) Date of publication of application:  
02.05.1990 Bulletin 1990/18

(73) Proprietor: **THE UNIVERSITY OF NORTH  
CAROLINA AT CHAPEL HILL**  
Chapel Hill, NC 27599-4100 (US)

(72) Inventors:

- FRENCH, Frank, S.  
Chapel Hill, NC 27514 (US)
- WILSON, Elisabeth, M.  
Chapel Hill, NC 27514 (US)
- JOSEPH, David, R.  
Chapel Hill, NC 27514 (US)
- LUBAHN, Dennis, B.  
Durham, NC 27713 (US)

(74) Representative: MacGregor, Gordon et al  
Eric Potter Clarkson,  
Park View House,  
58 The Ropewalk  
Nottingham NG1 5DD (GB)

(56) References cited:  
WO-A-89/09223

- PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE USA, vol. 85, October 1988, pages 7211-7215; C. CHANG et al.: "Structural analysis of complementary DNA and amino acid sequences of human and rat androgen receptors"
- PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE USA, vol. 86, no. 1, January 1989, pages 327-331, Washington, DC, US; W.D. TILLEY et al.: "Characterization and expression of cDNA encoding the human androgen receptor"
- MOLECULAR ENDOCRINOLOGY, vol. 2, no. 12, December 1988, pages 1265-1275; D.B. LUBAHN et al.: "The human androgen receptor: complementary deoxyribonucleic acid cloning, sequence analysis and gene expression in prostate"
- BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 104, no. 4, 1982, pages 1279-1286; J.A. FOEKENS et al.: "Purification of the androgen receptor of sheep seminal vesicles"
- Biochemical and Biophysical Research Communications, Volume 153 issued 31 May 1988, TRAPMAN "Cloning Structure and Expression of a cDNA Encoding the Human Androgen Receptor" see pages 241-248, especially figures 2 and 3.
- CHEMICAL ABSTRACTS, Volume 109(23) issued 05 December 1988 GOVINDAN "Cloning of the Human Androgen Receptor cDNA" see page 205.

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 0 365 657 B1

Best Available Copy

- Science, Volume 240, issued 15 April 1988  
LUBAHN "Cloning of Human Androgen Receptor Complementary DNA Localization to the X Chromosome". see pages 327-330.
- Science, Volume 240, issued 15 April 1988  
CHANG "Molecular Cloning of Human and Rat Complementary DNA Encoding Androgen Receptors" see pages 324-326.
- Nature, Volume 324, issued 18/25 December 1986 WEIMBERGER "The c-erb-A Gene Encodes a Thyroid Hormone Receptor" see pages 641-646. especially first paragraph page 641.
- Nature, Volume 320 issued 13 March 1986  
GREEN "Human Oestrogen Receptor cDNA. Sequence, Expression and Homology to v-erb-A.

**Description**

[0001] This invention was made in the course of research supported in part by grants from the National Institutes of Health (NIH HD 16910, HD 04466, and HD 18968).

**TECHNICAL FIELD OF THE INVENTION**

[0002] This invention relates to recombinant DNA molecules and their expression products. More specifically this invention relates to recombinant DNA molecules coding for androgen receptor protein, androgen receptor protein, and use of the DNA molecules and protein in investigatory, diagnostic and therapeutic applications.

**BACKGROUND OF THE INVENTION**

[0003] The naturally occurring androgenic hormones, testosterone and its 5 $\alpha$ -reduced metabolite, dihydrotestosterone, are synthesized by the Leydig cells of the testes and circulate throughout the body where they diffuse into cells and bind to the androgen receptor protein ("AR"). Androgens, acting through their receptor, stimulate development of the male genitalia and accessory sex glands in the fetus, virilization and growth in the pubertal male, and maintenance of male virility and reproductive function in the adult. The androgen receptor, together with other steroid hormone receptors constitute a family of trans-acting transcriptional regulatory proteins that control gene transcription through interactions with specific gene sequences.

[0004] When prostate cancer is found to be confined to the prostate gland, the treatment of choice is surgical removal. However, 50 to 80% of prostate cancer patients already have metastases at the time of diagnosis. Most of their tumors (70 to 80%) respond to the removal of androgen by castration or by suppression of luteinizing hormone secretion by the pituitary gland using a gonadotropin releasing hormone analogue alone or in combination with an anti-androgen. The degree and duration of response to this treatment is highly variable (10% live < 6 months, 50% live < 3 years, and 10% live > 10 years.) Initially cancer cells regress without androgen stimulation, but ultimately the growth of androgen independent tumor cells continues (35). At present it is not possible to predict on an individual basis which patient will respond to hormonal therapy and for how long. If poorly responsive patients could be identified early, they could be treated by alternative forms of therapy (e.g. chemotherapy) at an earlier stage when they might be more likely to respond.

[0005] Studies on androgen receptors in prostate cancer have suggested that a positive correlation may exist between the presence of androgen receptors in cancer cells and their dependence on androgenic hormone stimulation for growth. (An analogous situation exists in mammary carcinoma where there is a correlation between estrogen receptors and regression of the tumor in response to estrogen withdrawal). However, methodological problems in the measurement of androgen receptors have prevented the routine use of androgen receptor assays in the diagnostic evaluation of prostate cancer. Prior to our preparation of androgen receptor antibodies, all androgen receptor assays were based on the binding of [<sup>3</sup>H]-labeled androgen. These assays have been unreliable in human prostate cancer tissue because of the extreme lability of the androgen binding site and the presence of unlabeled androgen in the tissue. Endogenous androgen occupies the binding site on the receptor and dissociates very slowly (t<sub>1/2</sub> 24-48 hr at OC). A further problem is that biopsy samples are quite small, making it difficult to obtain sufficient tissue for [<sup>3</sup>H]-androgen binding assays. Moreover, prostate cancer is heterogenous with respect to cell types. Thus within a single biopsy sample there is likely to be an uneven distribution of cells containing androgen receptors.

[0006] Development of the male phenotype and maturation of male reproductive function are dependent on the interaction of androgenic hormones with the androgen receptor protein and the subsequent function of the receptor as a trans-acting inducer of gene expression. It has become well established over the past twenty-five years that genetic defects of the androgen receptor result in a broad spectrum of developmental and functional abnormalities ranging from genetic males (46,XY) with female phenotype to phenotypically normal males with infertility. Isolation of the structural gene for the androgen receptor makes it possible to define the nature of these genomic defects in molecular terms. Analysis of the functional correlates of the genetic defects may lead to a better understanding of the regulation of androgen receptor gene expression and of the mechanism of androgen action in male sexual development and function.

[0007] The androgen insensitivity syndrome, known also as testicular feminization, is characterized by an inability to respond to androgen due to a defect in the androgen receptor, the protein that mediates the action of androgen within the cell. Androgen insensitivity is an inherited X-linked trait that occurs in both complete and incomplete forms. The complete form results in failure of male sex differentiation during embryogenesis and absence of virilization at puberty. The result is a 46,XY genetic male with testes and male internal ducts. The testes produce normal amounts of testosterone and Mullerian inhibiting substance. Consequently development of the uterus is inhibited as in the normal male. Because of the inability to respond to androgen, the external genitalia remain in the female phenotype with

normal clitoris and labia. A small vagina develops from the urogenital sinus and ends in a blind pouch. At puberty feminization with breast development and female contours occur in response to testicular estrogen, however, there is no growth of sexual hair even though circulating testosterone concentrations are equal to or greater than levels in the normal male.

[0008] Incomplete forms of the androgen insensitivity syndrome include a spectrum of phenotypes resulting from varying degrees of incomplete androgen responsiveness. At one extreme, individuals have mild enlargement of the clitoris and sparse pubic hair. The opposite extreme is characterized by more complete masculinization with varying degrees of hypospadias deformity but predominantly a male phenotype. It has been reported that some adult men with severe oligospermia or azospermia who are otherwise normal, have defects in the androgen receptor. These may include as many as 10% of infertile males.

[0009] The genetic defect eliciting this range of abnormalities is thought to be a single biochemical event at the level of the gene for the androgen receptor. The androgen receptor is a high affinity androgen binding protein that mediates the effects of testosterone and dihydrotestosterone by functioning as a trans-acting inducer of gene expression. For proper male sexual development to occur, there is a requirement for androgen and its receptor at a critical time during embryogenesis and during puberty. The majority of individuals with the androgen insensitivity syndrome have a history of affected family members, although about a third are thought to represent new mutations of this X-linked disorder. The incidence ranges from 1 in 20,000 to 60,000 male births.

[0010] In studies of families with clinical evidence of the androgen insensitivity syndrome, four main categories were recognized that range from the most severe, complete absence of receptor binding activity in a genetic male with female phenotype, to qualitatively normal receptor in affected individuals. Second in severity are affected individuals with qualitatively abnormal androgen binding by receptor present in normal levels. Examples include the failure of sodium molybdate (a reagent often used in studies on steroid receptors) to stabilize the receptor of affected individuals when molybdate is known to stabilize the wild-type receptor. Lability of the receptor under conditions that normally cause transformation has also been reported. A third group expresses a decreased amount of receptor with wild-type in vitro binding characteristics. The final grouping contains those androgen insensitivity patients in whom no abnormality in receptor is detected. In a recent study of this form of the syndrome, the androgen receptor was as capable of binding oligonucleotides as the wild-type receptor. Indeed, with the techniques available until only recently, it has been difficult in certain cases to document an androgen receptor defect in affected individuals.

[0011] Experimental methods used in assessing receptor defects in the past have relied on the ability of receptor to bind androgen with high affinity. The limitation of this methodology is that it is not possible to distinguish between the lack of expression of the receptor and loss of androgen binding activity. An example of how inadequate methodology complicates diagnosis is the absence of detectable receptor binding activity in patients who are partially virilized. It is theoretically possible for a mutation to occur which allows the receptor with defective androgen binding activity to induce gene transcription. Biologically active truncated forms of the glucocorticoid receptor that lack steroid binding activity but retain the DNA binding domain have been demonstrated using genetically engineered mutants.

[0012] Purification of the androgen receptor has been difficult to accomplish due to its low concentration and high degree of instability. Reported attempts at purification using either conventional methods of column chromatography or steroid-affinity chromatography have yielded insufficient amounts of receptor protein to allow even the preparation of monoclonal antibodies.

[0013] An early report on the partial purification of the androgen receptor was disclosed by Mainwaring et al. in "The use of DNA - cellulose chromatography and isoelectric focusing for the characterization and partial purification of steroid-receptor complexes," *Biochem.J.*, 134, 113-127 (1973). They used DNA-cellulose chromatography and isoelectric focusing to isolate the receptor from rat ventral prostate and determined its physiochemical properties. This group was among the first to attempt the use of steroid affinity chromatography in conjunction with conventional chromatography, using the affinity label 17B-bromoacetoxytestosterone in receptor purification (See Mainwaring et al., "Use of the affinity label 17B-bromoacetoxytestosterone in the purification of androgen receptor proteins," *Perspectives in Steroid Receptor Research*, (1980)). Partial purification of androgen receptor has also been attempted from other tissue sources, such as ram seminal vesicles (See Foekens et al., *Molecular Cellular Endocr*, 23, 173-186 (1981) and Foekens et al., "Purification of the androgen receptor of sheep seminal vesicles," *Biochem Biophys Res Comm*, 104, 1279-1286 (1982)). The partially purified receptor displayed characteristics of a proteolyzed receptor, but a purification of 2,000 fold was reported with a recovery of 33% (See Foekens et al., "Purification of the androgen receptor of sheep seminal vesicles," *Biochem Biophys Res Comm*, 104, 1279-1286 (1982)). Later attempts at purification continued to combine steroid affinity chromatography with conventional techniques, reportedly achieving significant purification, but recoveries too low for further analysis (See Chang et al., "Purification and characterization of androgen receptor from steer seminal vesicle," *Biochemistry* 21, 4102-4109 (1982), Chang et al., "Purification and characterization of the androgen receptor from rat ventral prostate," *Biochemistry* 22, 6170-6175 (1983) and Chang et al., "Affinity labeling of the androgen receptor in rat prostate cytosol with 17B-[(bromoacetyl)oxy]-5-alpha-androstan-3-one," *Biochemistry* 23, 2527-2533 (1984)). More recent studies examine the effectiveness of a variety of immobilized androgens for their ability

to bind the androgen receptor (See De Larminat et al., "Synthesis and evaluation of immobilized androgens for affinity chromatography in the purification of nuclear androgen receptor," *The Prostate* 5, 123-140 (1984) and Bruchovsky et al., "Chemical demonstration of nuclear androgen receptor following affinity chromatography with immobilized ligands," *The Prostate* 10, 207-222 (1987)). Despite these efforts, the receptor has not been purified to homogeneity and the quantities of purified androgen receptor obtained have been insufficient for the production of antisera.

[0014] Clinical assays for the androgen receptor now include several methods. The most common is the binding of tritium-labeled hormone and measurement of binding using a charcoal adsorption assay. Either a natural androgen, such as dihydrotestosterone, or synthetic androgen, such as mibolerone or methyltrienolone (R1881), can be used. An advantage of the latter in human tissue is that it is not significantly metabolized and does not bind to the serum androgen binding protein, sex steroid binding globulin. A limitation of radioisotope labeling of receptor is interference caused by endogenous androgen. Although exchange assays for the androgen receptor have been described (See Carroll et al., *J Steroid Biochem* 21, 353-359 (1984) and Traish et al., *J Steroid Biochem* 23, 405-413 (1985)), their effectiveness is limited by the slow kinetics of dissociation of the endogenous receptor-bound androgen.

[0015] Another method used to assess receptor status is autoradiography. In this method disclosed in Barrack et al., "Current concepts and approaches to the study of prostate cancer," *Progress in Clinical and Biological Research*, 239, 155-187 (1987) the radioactively labeled androgen is incubated with slide-mounted tissue sections of small tissue biopsy specimens which are then frozen, sectioned and fixed. Nuclear localization of radioactivity is detected by exposure of tissue sections to x-ray film. This technique requires considerable technical expertise, is labor intensive, and requires extended periods of exposure time. It is therefore of limited usefulness in general clinical assays. Another problem is high levels of background signal, i.e. a high noise/signal ratio, making it difficult to distinguish receptor-bound nuclear radioactivity from unbound radioactivity distributed throughout the cells.

[0016] WO 87/05049 (Shine) discloses a method for the production of purified steroid receptor proteins, specifically estrogen receptor proteins, through the expression of recombinant DNA encoding for such proteins in eukaryotic host cells. However, the reference does not disclose the sequence for androgen receptor protein, nor does it disclose a method for obtaining such a sequence.

[0017] EP-A-407462 is a document which falls within the definition of Article 54(3) EPC.

#### SUMMARY OF THE INVENTION

[0018] The present invention provides a recombinant DNA molecule comprising a DNA sequence that encodes for a human polypeptide which polypeptide has substantially the same biological activity as human androgen receptor protein whose amino acid sequence is shown in Figure 4 or encodes the complete amino acid sequence of Figure 4 and (i) does not hybridise under stringent conditions to a DNA molecule which codes for the following polypeptide

[illegible]

and (ii) is not degenerate with the said DNA molecule and (iii) is not the DNA molecule shown above. A DNA sequence encoding androgen receptor protein or a protein having substantially the same biological activity as androgen receptor activity is described. DNA sequences may be obtained from cDNA or genomic DNA, or prepared using DNA synthesis techniques.

**[0019]** The invention further provides a cloning vehicle comprising a DNA molecule which upon expression in a host produces a human polypeptide which polypeptide has substantially the same biological activity as human androgen receptor protein whose amino acid sequence is shown in Figure 4 or encodes the complete amino acid sequence of Figure 4 wherein the DNA molecule (i) does not hybridise under stringent conditions to a DNA molecule which codes for the following polypeptide

[illegible]

and (ii) is not degenerate with the said DNA molecule and (iii) is not the DNA molecule shown above. Cloning vehicles comprising a DNA sequence encoding androgen receptor protein or a protein having substantially the same biological activity as androgen receptor protein are described. The cloning vehicles further comprise a promoter sequence upstream of and operatively linked to the DNA sequence. In general the cloning vehicles will also contain a selectable marker, and, depending on the host cell used, may contain such elements as regulatory sequences, polyadenylation signals, enhancers and RNA splice sites.

40 [0020] Cells transfected or transformed to produce androgen receptor protein or a protein having substantially the same biological activity as androgen receptor protein are described.

**[0021]** A purified androgen receptor protein and purified polypeptides and proteins having substantially the same biological activity as androgen receptor activity, and methods for producing such proteins and polypeptides are described.

45 **[0022]** The invention further provides the use of a probe comprising complementary DNA sequences derived from the deduced sequences encoding androgen receptor as shown in Figure 4 in the manufacture of a reagent to detect the presence of androgen receptor mRNA in tumour cells or to detect abnormalities in the androgen receptor gene or in its mRNA provided that the probe (i) does not hybridise under stringent conditions to a DNA molecule which codes for the polypeptide

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210 211 212 213 214 215 216 217 218 219 220 221 222 223 224 225 226 227 228 229 230 231 232 233 234 235 236 237 238 239 240 241 242 243 244 245 246 247 248 249 250 251 252 253 254 255 256 257 258 259 260 261 262 263 264 265 266 267 268 269 270 271 272 273 274 275 276 277 278 279 280 281 282 283 284 285 286 287 288 289 290 291 292 293 294 295 296 297 298 299 300 301 302 303 304 305 306 307 308 309 310 311 312 313 314 315 316 317 318 319 320 321 322 323 324 325 326 327 328 329 330 331 332 333 334 335 336 337 338 339 340 341 342 343 344 345 346 347 348 349 350 351 352 353 354 355 356 357 358 359 360 361 362 363 364 365 366 367 368 369 370 371 372 373 374 375 376 377 378 379 380 381 382 383 384 385 386 387 388 389 390 391 392 393 394 395 396 397 398 399 400 401 402 403 404 405 406 407 408 409 410 411 412 413 414 415 416 417 418 419 420 421 422 423 424 425 426 427 428 429 430 431 432 433 434 435 436 437 438 439 440 441 442 443 444 445 446 447 448 449 450 451 452 453 454 455 456 457 458 459 460 461 462 463 464 465 466 467 468 469 470 471 472 473 474 475 476 477 478 479 480 481 482 483 484 485 486 487 488 489 490 491 492 493 494 495 496 497 498 499 500 501 502 503 504 505 506 507 508 509 510 511 512 513 514 515 516 517 518 519 520 521 522 523 524 525 526 527 528 529 530 531 532 533 534 535 536 537 538 539 540 541 542 543 544 545 546 547 548 549 550 551 552 553 554 555 556 557 558 559 560 561 562 563 564 565 566 567 568 569 570 571 572 573 574 575 576 577 578 579 580 581 582 583 584 585 586 587 588 589 590 591 592 593 594 595 596 597 598 599 600 601 602 603 604 605 606 607 608 609 610 611 612 613 614 615 616 617 618 619 620 621 622 623 624 625 626 627 628 629 630 631 632 633 634 635 636 637 638 639 640 641 642 643 644 645 646 647 648 649 650 651 652 653 654 655 656 657 658 659 660 661 662 663 664 665 666 667 668 669 670 671 672 673 674 675 676 677 678 679 680 681 682 683 684 685 686 687 688 689 690 691 692 693 694 695 696 697 698 699 700 701 702 703 704 705 706 707 708 709 710 711 712 713 714 715 716 717 718 719 720 721 722 723 724 725 726 727 728 729 730 731 732 733 734 735 736 737 738 739 740 741 742 743 744 745 746 747 748 749 750 751 752 753 754 755 756 757 758 759 760 761 762 763 764 765 766 767 768 769 770 771 772 773 774 775 776 777 778 779 780 781 782 783 784 785 786 787 788 789 790 791 792 793 794 795 796 797 798 799 800 801 802 803 804 805 806 807 808 809 810 811 812 813 814 815 816 817 818 819 820 821 822 823 824 825 826 827 828 829 830 831 832 833 834 835 836 837 838 839 840 841 842 843 844 845 846 847 848 849 850 851 852 853 854 855 856 857 858 859 860 861 862 863 864 865 866 867 868 869 870 871 872 873 874 875 876 877 878 879 880 881 882 883 884 885 886 887 888 889 890 891 892 893 894 895 896 897 898 899 900 901 902 903 904 905 906 907 908 909 910 911 912 913 914 915 916 917 918 919 920 921 922 923 924 925 926 927 928 929 930 931 932 933 934 935 936 937 938 939 940 941 942 943 944 945 946 947 948 949 950 951 952 953 954 955 956 957 958 959 960 961 962 963 964 965 966 967 968 969 970 971 972 973 974 975 976 977 978 979 980 981 982 983 984 985 986 987 988 989 990 991 992 993 994 995 996 997 998 999 1000 1001 1002 1003 1004 1005 1006 1007 1008 1009 1010 1011 1012 1013 1014 1015 1016 1017 1018 1019 1020 1021 1022 1023 1024 1025 1026 1027 1028 1029 1030 1031 1032 1033 1034 1035 1036 1037 1038 1039 104

and (ii) does not hybridise under stringent conditions to DNA molecule which codes for the polypeptide



5

10

15

20

25

30

and (iii) is not degenerate with either of the said DNA molecules and (iv) is not either of the DNA molecules shown above.

35 BRIEF DESCRIPTION OF THE DRAWINGS

40

49

50

55 [0024] Abbreviations for amino acid residues are:

A, Ala; C, Cys; D, Asp; E, Glu; F, Phe; G, Gly; H, His; I, Ile; K,  
 Lys; L, Leu; M, Met; N, Asn; P, Pro; Q, Gln; R, Arg; S, Ser; T, Thr;  
 V, Val; W, Trp; and Y, Tyr.

[0025] Figure 2 illustrates the steroid binding properties of expressed AR cDNA. (A) shows the structure of pCMVAR in the expression vector pCMV containing the human cytomegalovirus(CMV) promoter of the immediate early gene, poly(A) addition-transcription terminator region of the human growth hormone gene (hGH poly A),SV40 origin of replication (SV40 Ori), and a polylinker region for insertion of cDNAs. The plasmid pTEBR contains the ampicillin resistance gene (Amp). (B) shows saturation analysis of [<sup>3</sup>H]dihydrotestosterone binding in extracts of pCMVAR transfection of COS M6 cells. Portions of cytosol (0.1 ml, 0.3 mg/ml protein) were incubated overnight at 4°C with increasing concentrations of <sup>3</sup>H-labeled hormone and analyzed by charcoal adsorption. Nonspecific binding increased from 18% to 37% of total bound radioactivity. (C) shows a Scatchard plot analysis of [<sup>3</sup>H]dihydrotestosterone binding. Error estimation was based on linear regression analysis (r=0.966). (U) illustrates the competition of unlabeled steroids for binding of 5 nM [<sup>3</sup>H]dihydrotestosterone in transfected COS M6 cell extracts. Unlabeled steroids were added at 10- and 100-fold excess of labeled hormone. Specific binding was determined as previously described.

[0026] Figure 3 is a compiled clone map of the human androgen receptor. The map shows the structure of the human androgen receptor gene and the relative positions of the nucleic acid sequences contained in the cDNA probes [A], [B], [C] and [D], human fibroblast clone [1], human epididymis clones [1] and [5], human genomic clones [1], [2], [3], [4] and [5], and rat epididymis clones [1] and [2].

[0027] Figure 4 shows the complete nucleotide sequence for human androgen receptor cDNA and the deduced amino acid sequence.

[0028] Figure 5 shows the complete nucleotide sequence of the rat androgen receptor cDNA and the predicted amino acid sequence.

[0029] Figure 6 is a photograph of a frozen section of rat ventral prostate stained with antibodies (AR-52-3-p) to the AR peptide NH<sub>2</sub>-Asp-His-Val-Leu-Pro-Ile-Asp-Tyr-Tyr-Phe-Pro-Pro-Gln-Lys-Thr in a dilution of 1 to 3000 using the avidin-biotin peroxidase technique. Androgen receptor is indicated by brown staining of nuclei in epithelial cells.

[0030] Figure 7 is a photograph showing restriction fragment length polymorphisms in the human androgen receptor gene.

[0031] Figure 8 is a photograph showing a Southern blot analysis in the human androgen receptor gene in complete androgen insensitivity syndrome patients.

## DETAILED DESCRIPTION OF THE INVENTION

[0032] In the description the following terms are employed:

### Nucleotide

[0033] A monomeric unit of DNA or RNA consisting of a sugar moiety (pentose), a phosphate, and a nitrogenous heterocyclic base. The base is linked to the sugar moiety via the glycosidic carbon (1' carbon of the pentose) and that combination of base and sugar is a nucleotide. The base characterizes the nucleotide. The four DNA bases are adenine ("A"), guanine ("G"), cytosine ("C") and thymine ("T"). The four RNA bases are A, G, C and uracil ("U"). A and G are purines, abbreviated to R, and C, T, and U are pyrimidines, abbreviated to Y.

### DNA Sequence

[0034] A linear series of nucleotides connected one to the other by phosphodiester bonds between the 3' and 5' carbons of adjacent pentoses.

### Codon

[0035] A DNA sequence of three nucleotides (a triplet) which encodes through mRNA an amino acid, a translational start signal or a translational termination signal. For example, the nucleotide triplets TTA, TTG, CTT, CTC, CTA and CTG encode for the amino acid leucine ("Leu"), TAG, TAA and TGA are translational stop signals and ATG is a translational start signal.

## EP 0 365 657 B1

### Reading Frame

[0036] The grouping of codons during translation of mRNA into amino acid sequences. During translation the proper reading frame must be maintained. For example, the sequence GCTGGTTGTAAG may be translated in three reading frames or phases, each of which affords a different amino acid sequence:

GCT GGT TGT AAG - Ala-Gly-Cys-Lys

G CTG GTT GTA AG - Leu-Val-Val

GC TGG TTG TAA A - Trp-Leu-(STOP)

Polypeptide

[0037] A linear series of amino acids connected one to the other by peptide bonds between the  $\alpha$ -amino and carboxy groups of adjacent amino acids.

### Genome

[0038] The entire DNA of a substance. It includes inter alia the structural genes encoding for the polypeptides of the substance, as well as operator, promoter and ribosome binding and interaction sequences including sequences such as the Shine-Dalgarno sequences.

### Structural Gene

[0039] A DNA sequence which encodes through its template or messenger RNA ("mRNA") a sequence of amino acids characteristic of a specific polypeptide.

### Transcription

[0040] The process of producing mRNA from a structural gene.

### Translation

[0041] The process of producing a polypeptide from mRNA.

### Expression

[0042] The process undergone by a structural gene to produce a polypeptide. It is a combination of transcription and translation.

### Plasmid

[0043] A non-chromosomal double-stranded DNA sequence comprising an intact "replicon" such that the plasmid is replicated in a host cell. When the plasmid is placed within a unicellular organism, the characteristics of that organism are changed or transformed as a result of the DNA of the plasmid. For example, a plasmid carrying the gene for tetracycline resistance ( $Tet^R$ ) transforms a cell previously sensitive to tetracycline into one which is resistant to it. A cell transformed by a plasmid is called a "transformant".

### Phage or Bacteriophage

[0044] Bacterial virus many of which include DNA sequences encapsidated in a protein envelope or coat ("capsid"). In a unicellular organism a phage may be introduced as free DNA by a process called transfection.

### Cloning Vehicle

[0045] A plasmid, phage DNA or other DNA sequences which are able to replicate in a host cell, characterized by one or a small number of endonuclease recognition sites at which such DNA sequences may be cut in a determinable

fashion without attendant loss of an essential biological function of the DNA, e.g., replication, production of coat proteins or loss of promoter or binding sites, and which contain a marker suitable for use in the identification of transformed cells, e.g., tetracycline resistance or ampicillin resistance. A cloning vehicle is often called a vector.

## 5 Cloning

[0046] The selection and propagation of a single species.

## Recombinant DNA Molecule

10

[0047] A hybrid DNA sequence comprising at least two nucleotide sequences, the first sequence not normally being found together in nature with the second.

## Expression Control Sequence

15

[0048] A DNA sequence of nucleotides that controls and regulates expression of structural genes when operatively linked to those genes.

[0049] To attain the objects of this invention it was necessary to determine the amino acid sequence and the DNA sequence of the structural gene encoding androgen receptor protein. One conventional approach would involve starting with the purified androgen receptor protein. However, as described above, significant amounts of the protein for such purposes have not been obtained.

20

[0050] An alternative approach to circumvent the overwhelming difficulty of androgen receptor protein purification is direct isolation of the DNA encoding the messenger RNA for androgen receptor protein.

[0051] Our strategy for isolating AR DNA was based on evidence that the AR gene is X-linked and that no other steroid receptor gene is located on the X chromosome. Sequence data are available from cDNAs for glucocorticoid, estrogen, progesterone, mineralocorticoid and vitamin D receptors. Comparison of the derived amino acid sequences has revealed a central region of high cysteine content which was found also in the v-erb A oncogene product recently identified as the thyroid hormone receptor. Within this 61-63 amino acid region is an arrangement of 9 cysteine residues that are absolutely conserved among steroid receptors thus far characterized. The overall homology among sequences in this conserved region ranges between 40 and 90%. We assumed that AR would resemble other members of the steroid receptor family in the conserved DNA-binding domain.

25

30

[0052] A human X chromosomal library was screened with the synthetic oligo nucleotide probe A (Oligo A sequence = 5' CTT TTG AAG AAG ACC TTA CAG CCC TCA CAG GT<sup>3</sup>) of Figure 1 (A) designed as a consensus sequence from the conserved sequence of the DNA-binding domain of other steroid receptors. Screening the library with the oligo A probe resulted in several recombinants whose inserts were cloned into bacteriophage M13 DNA and sequenced. One recombinant clone (Charon 35 X05AR) (human genomic clone [1]) contained a sequence similar to, yet distinct from, the DNA-binding domains of other steroid receptors. It had 84% sequence identity with oligo A, while other receptor DNAs were 78% to 91% homologous with the consensus oligonucleotide.

35

[0053] From the nucleotide sequence just 5' of the DNA binding domain, oligonucleotide probe B (Oligo B sequence = 5' GGA CCA TGT TTT GCC CAT TGA CTA TTA CTT TCC ACC CC<sup>3</sup>) was synthesized and used to screen bacteriophage lambda gt10 cDNA libraries from human epididymis and cultured human foreskin fibroblasts. Recombinant phage (unamplified) screened with this oligonucleotide by in situ hybridization revealed one positive clone in each library. The epididymal clone (gt10 ARHEL1)(human epididymis clone [1]) contained the complete DNA-binding domain and approximately 1.5 kb of upstream sequence, whereas the fibroblast clone (gt10 ARHFL1)(human fibroblast clone [1]) shown in Figure 1(B) contained the DNA-binding domain and 1.5 kb of downstream sequence. The DNA-binding domains of the cDNA isolates were identical to that of the genomic exon sequence.

45

[0054] Transient expression in monkey kidney cells (COS M6) demonstrated that the human foreskin fibroblast cDNA fragment encodes the steroid-binding domain of hAR. A DNA fragment (ARHFLIH-X) extending 5' to 3' from the Hind III site within the putative DNA-binding domain through the stop codon (TGA) was cloned into pCMV as shown in Figure 2(A). Expression was facilitated by adding to the 5' end a consensus translation initiation sequence containing the methionine codon (ATG) in reading frame. Transfection of the recombinant construct produced a protein with high-affinity for [<sup>3</sup>H]dihydrotestosterone, Figure 2(C) saturable at physiological levels of hormone. See Figure 2(B). The binding constant [ $K_d = 2.7 (+ 1.4) \times 10^{-10}$  M] was nearly identical to that of native AR. The level of expressed protein, 1.3 pmol per milligram of protein, was 20 to 60 times greater than that in male reproductive tissues. Mock transfections without plasmid or transfections with plasmid DNA lacking the AR insert yielded no specific binding of dihydrotestosterone. Figure 2(D) shows steroid specificity was identical to that of native AR, with highest affinity for dihydrotestosterone and testosterone, intermediate affinity for progesterone and estradiol, and low affinity for cortisol.

55

[0055] Figure 3 is a clone map compiled to show the human androgen receptor gene and the nucleic acid sequences

in the cDNA clones, human genomic clones, human fibroblast clones, human epididymis clones, and rat epididymis clones. Human fibroblast clone [1] extended through the stop codon or the C-terminal end of the androgen receptor protein. To isolate and elucidate the sequence of the 5' or N-terminal end of the androgen receptor protein, we used a EcoRI/SstI fragment (EcoRI site was from the linker) from the 5' end of human epididymis clone [1] as a probe (cDNA probe [A]), to rescreen the human X chromosomal library by standard techniques. By these techniques, human genomic clone [2] was isolated and in turn used as a probe to rescreen a human epididymis library and isolate human epididymis clone [5]. The N-terminal sequence was elucidated along with the 5' flanking sequence of the androgen receptor protein and gene. Human genomic clones [3], [4] and [5] for the sequence 3' of human genomic clone [1] were obtained using cDNA probes B [a Hind III/EcoRI fragment] and C [an EcoRI fragment], by screening and isolating by standard techniques.

[0056] Two rat clones, rat epididymis clones [1] and [2], were isolated from a rat epididymis cDNA library using as probes the complete human epididymis clone [1] and a EcoRI/PstI fragment, cDNA probe [D], respectively. These rat clones contained the entire protein coding sequence for the rat androgen receptor, plus flanking 5' and 3' untranslated sequences which were used to confirm the sequence of the human androgen receptor.

[0057] The complete double-stranded sequence encoding the human androgen receptor protein was determined and the deduced amino acid sequence of the human androgen receptor protein is set forth in Figure 4. The cDNA sequence and the amino acid sequence for the rat androgen receptor protein is set forth in Figure 5.

[0058] Recombinant DNA clones human fibroblast clone [1] isolated from human foreskin fibroblast cDNA gt11 expression library, human epididymis clones [1] and [5] isolated from human epididymis cDNA gt11 expression library were deposited in the American Type Culture Collection with accession numbers ATCC # 40439, ATCC # 40442 and ATCC # 40440 respectively. Human genomic clones [1], [2], [3], [4] and [5] which were isolated from human X chromosome lambda Charon 35 library available as ATCC # 57750 have been deposited with the American Type Culture Collection with accession numbers ATCC # 40441, ATCC # 40443, ATCC # 40444, ATCC # 40445 and ATCC # 40446 respectively.

[0059] A wide variety of host-cloning vehicle combinations may be usefully employed in cloning the double stranded DNA disclosed herein. For example, useful cloning vehicles may include chromosomal, non-chromosomal and synthetic DNA sequences such as various known bacterial plasmids and wider host range plasmids such as pCMV and vectors derived from combinations of plasmids and phage DNA such as plasmids which have been modified to employ phage DNA expression control sequences. Useful hosts may include bacterial hosts, yeasts and other fungi, animal or plant hosts, such as Chinese Hamster Ovary cells (CHO, or monkey kidney cells (COS M6), and other hosts. The particular selection of host-cloning vehicle combinations may be made by those of skill in the art after due consideration of factors such as the source of the DNA- i.e. genomic or cDNA.

[0060] Cloning vehicles for use in carrying out the present invention will further comprise a promoter operably linked to the DNA sequence encoding the androgen receptor protein. In some instances it is preferred that cloning vehicles further comprise an origin of replication, as well as sequences which regulate and/or enhance expression levels, depending on the host cell selected.

[0061] Techniques for transforming hosts and expressing foreign cloned DNA in them are well known in the art (See, for example, Maniatis et al., *infra*). Cloning vehicles used for expressing foreign genes in bacterial hosts will generally contain a selectable marker, such as a gene for antibiotic resistance, and a promoter which functions in the host cell.

[0062] Eukaryotic microorganisms, such as the yeast *Saccharomyces cerevisiae*, may also be used as host cells. Cloning vehicles will generally comprise a selectable marker, such as the nutritional marker TRP, which allows selection in a host strain carrying a *trp1* mutation. To facilitate purification of an androgen receptor protein produced in a yeast transformant, a yeast gene encoding a secreted protein may be joined to the sequence encoding androgen receptor protein.

[0063] Higher eukaryotic cells can also serve as host cells in carrying out the present invention. Cultured mammalian cells are preferred. Cloning vehicles for use in mammalian cells will comprise a promoter capable of directing the transcription of a foreign gene introduced into a mammalian cell. Also contained in the expression vector is a polyadenylation signal, located downstream of the insertion site. The polyadenylation signal can be that of the cloned androgen receptor gene, or may be derived from a heterologous gene.

[0064] A selectable marker, such as a gene that confers a selectable phenotype, is generally introduced into the cells along with the gene of interest. Preferred selectable markers include genes that confer resistance to drugs, such as neomycin, hygromycin and methotrexate. Selectable markers may be introduced into the cell on a separate plasmid at the same time as the gene of interest, or they may be introduced on the same plasmid.

[0065] The copy marker of the integrated gene sequence can be increased through amplification by using certain selectable markers. Through selection, expression levels may be substantially increased.

[0066] Androgen receptor proteins may be purified from the host cells or cell media according to the present invention using techniques well known to those in the art. Such proteins may be utilized to produce monoclonal or polyclonal antibodies according to the techniques described below.

[0067] The techniques of this invention offer considerable advances over existing technology for measurement of androgen receptor. Utilizing proteins and peptides containing the disclosed sequences monoclonal or polyclonal antibodies can be produced for use as immunochemical reagents in immunodiagnostic assays. For example, radioimmunoassays and ELISA assays can be developed utilizing these reagents which will allow detection and quantification of androgen receptor in the presence of endogenous androgen since such androgen will not interfere with antibody binding to the receptor.

[0068] Immunocytochemistry utilizing our reagents enables determination and quantification of the cellular distribution of the androgen receptor in tumor tissues, which are often heterogenous in composition. This assay offers great potential for diagnostic evaluation of prostate cancer to determine responsiveness to androgen withdrawal therapy.

[0069] In addition, the antibodies produced using the disclosed amino acid sequences can also be used in processes for the purification of androgen receptor protein produced by the above methods. One such purification process is disclosed in Logeat, F., et al., *Biochemistry* vol. 24 (1985), pp. 1029-1035, which is incorporated by reference herein.

[0070] Androgen receptor proteins and polypeptides synthesized from the deduced amino acid sequence can be used as immunogens for the preparation of antibodies to the androgen receptor. Peptides for such use range in length from about 3 to about 958 amino acids in length and are preferably from about 15 to about 30 amino acids in length. Shorter peptides may have significant sequence homology to other steroid receptor proteins and larger peptides may contain multiple antigenic determinants; these properties could result in antibodies with cross-reactivities to other steroid receptor proteins.

[0071] Peptides can be synthesized from amino acid sequences in the NH<sub>2</sub>-terminal region, the DNA-binding domain, and the carboxyl-terminal steroid binding domain. Peptide selection will be based on hydropathic plots, selecting hydrophilic regions that are more likely exposed on the receptor surface. For diagnostic purposes preferred sequences will be selected from the NH<sub>2</sub>-terminal region where there is the least homology with other steroid receptor proteins.

[0072] Peptides for use as immunogens can be synthesized using techniques available to one of ordinary skill in the art. For example, peptides corresponding to androgen receptor sequences can be synthesized using tBOC chemistry on a Bioscience Model 9500 peptide synthesizer. Peptide purity is assessed by high pressure liquid chromatography. Peptides can be conjugated to keyhole limpet hemocyanin through cysteine residues using the coupling agent m-maleimido-benzoyl-N-hydroxysuccinimide ester. One can also prepare resin-bound peptides utilizing the p-(oxymethyl benzamide) handle to attach the C-terminal amino acid to solid-phase resin support.

[0073] Proteins and peptides of this invention can be utilized for the production of polyclonal or monoclonal antibodies. Methods for production of such antibodies are known to those of ordinary skill in the art and may be performed without undue experimentation. One method for the production of monoclonal antibodies is described in Kohler, G., et al., "Continuous Culture of Fused Cells Secreting Antibody of Predetermined Specificity," *Nature*, vol. 256 (1975), p. 495, which is incorporated herein by reference. Polyclonal antibodies, by way of example, can be produced by the method described below.

[0074] Peptide conjugates or resin-bound peptides can be injected into rabbits according to the procedure of Vaitukaitis et al., *J Clin Endocrinol Metab*, 33, 988-991 (1971) using a standard immunization schedule. Antisera titers can be determined in the ELISA assay.

[0075] For example, one androgen receptor sequence, NH<sub>2</sub>-Asp-His-Val-Leu-Pro-Ile-Asp-Tyr-Tyr-Phe-Pro-Pro-Gln-Lys-Thr in the 5' region upstream from the DNA-binding domain, was used to raise antisera in rabbits. The antisera react selectively at a dilution of 1 to 500 with the androgen receptor both in its untransformed 8-10S form and in its 4-5S transformed form. Receptor sedimentation on sucrose gradients increases from 4 to 8-10S in the presence of antiserum at high ionic strength and from 8-10S to 11-12S at low ionic strength sucrose gradients. In the ELISA reaction against the peptide used as immunogen, reactivity was detectable at 1 to 25,000 dilution. This antiserum at a dilution of 1 to 3000 was found effective in staining nuclear androgen receptor in rat prostate and other male accessory sex glands (see Figure 6).

[0076] Our invention provides new molecular probes comprising complementary DNA sequences derived from the deduced sequences encoding the androgen receptor for diagnostic purposes. Such probes may be used to detect the presence of androgen receptor mRNA in tumor cells. Such probes may also be used for detection of androgen receptor gene defects. Androgen receptor complementary DNA sequences can be used as hybridization probes to detect abnormalities in the androgen receptor gene or in its messenger RNA.

[0077] Androgen receptor DNA sequences disclosed and complementary RNA sequences can be used to construct probes for use in DNA hybridization assays. An example of one such hybridization assay and methods for constructing probes for such assays are disclosed in U.S. Patent No. 4,683,195 to Mullis et al., U.S. Patent No. 4,683,202 to Mullis, U.S. Patent No. 4,617,261 to Sheldon, III et al., U.S. Patent No. 4,683,194 to Salki et al., and U.S. Patent No. 4,705,886 to Levenson et al., which are hereby incorporated by reference.

[0078] By example, one method for detecting gene deletion utilizes Southern blotting and hybridization. DNA can be isolated from cultured skin fibroblasts or from leukocytes obtained from blood. DNA is cut with restriction enzymes, electrophoresed on an agarose gel, blotted onto nitrocellulose, and hybridized with [<sup>32</sup>P]-labeled androgen receptor

DNA (see Maniatis, T. et al., Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory, 1982, incorporated by reference herein).

[0079] In addition, small mutations can be detected utilizing methods known to one of ordinary skill in the art, from cultured skin fibroblasts of the affected individual. A cDNA library can be prepared using standard techniques. The androgen receptor clones can be isolated using a [<sup>32</sup>P] DNA AR probe. The clones AR cDNA can then be sequenced and compared to normal AR cDNA sequences.

[0080] Alternatively genomic DNA can be isolated from blood leukocytes or cultured skin fibroblasts of the affected individual. The DNA is then subjected to restriction enzyme digestion, electrophoresis and is blotted onto nitrocellulose. Synthetic oligonucleotides can be used to bracket specific exons. Exon sequences are amplified using the polymerase chain reaction, cloned into M13 and sequenced. The sequences are compared to normal human AR DNA sequences.

[0081] Another method of identifying small mutations or deletions takes advantage of the ability of RNase A to cleave regions of single stranded RNA in RNA:DNA hybrids. Genomic DNA isolated from fibroblasts of affected individuals is hybridized with radioactive RNA probes (Promega Biotec) prepared from wild-type androgen receptor cDNA. Mismatches due to mutations would be cleaved by RNase A and result in altered sized bands relative to wild-type on denaturing polyacrylamide gels.

[0082] Restriction fragment length polymorphism (RFLP) linked to the androgen receptor gene locus may be used in prenatal diagnosis and carrier detection of androgen insensitivity. For example, the presence of RFLPs in normal individuals is first established by isolating DNA from lymphocytes of at least six females (total of 12 X chromosomes). DNA can be isolated using the proteinase K procedure and fragmented using a battery of restriction enzymes. Preferred are those enzymes that contain the dinucleotide sequence CG in their recognition sequence. Southern blots are screened with 5-10 kb androgen receptor genomic fragments which if possible lack repetitive DNA. For those regions containing repetitive elements, total human genomic DNA can be added as competitor in the hybridization reaction. Alternatively, one can subclone selected regions to yield a probe free of repetitive elements.

[0083] For example, a human restriction fragment length was determined by cDNA probe (B) and Hind III restriction endonuclease using the Southern blot technique (See Figure 7). The two RFLP alleles detected are a fragment at 6.5 kb (allele 1) and a fragment at 3.5 kb (allele 2). Major constant fragment bands are seen at approximately 2 and 5 kb with minor constant bands at 0.9 and 7.5 kb. Allele 1 is present in approximately 30% of the X chromosomes of the Caucasian population. Allele 2 is present in approximately 20% of the X chromosomes of the Caucasian population. In Figure 8 Lanes A, B and D, DNA from women who are homozygous for allele 1 is shown. In Figure 8 Lane C, DNA from a woman who is heterozygous for both alleles 1 and 2 is shown. Figure 8 Lane E contains DNA from a man that only possesses allele 2. This RFLP, and others determined by the clones we have isolated, will enable one to monitor the androgen receptor gene in various disease conditions described herein.

[0084] An example of using the androgen receptor clones to detect mutations is shown in Figure 8 where five different complete androgen insensitive patients' DNA are digested with EcoRI, electrophoresed on a Southern blot, and probed with cDNA probe B. The patient in lane B lacks a 3kb band indicating that part of the androgen receptor gene is deleted. Further analysis of this and other patients DNA is possible with other AR probes and by sequencing by standard methods and comparing the abnormal sequence to the normal sequence described herein.

[0085] Other potential uses for oligonucleotide sequences disclosed, for example in construction of therapeutics to block genetic expression, will be obvious to one of ordinary skill in the art.

#### Claims

1. A recombinant DNA molecule comprising a DNA sequence that encodes for a human polypeptide which polypeptide has substantially the same biological activity as human androgen receptor protein whose amino acid sequence is shown in Figure 4 or encodes the complete amino acid sequence of Figure 4 and (i) does not hybridise under stringent conditions to a DNA molecule which codes for the following polypeptide







5

10

15

20

25

30

35

40

45

50

55

and (ii) does not hybridise under stringent conditions to DNA molecule which codes for the polypeptide

15

20

25

30

35

40

45

50

## 55

- 19

unter stringenten Bedingungen nicht mit einem DNA-Molekül hybridisiert, das für das folgende Polypeptid codiert:

[illegible]

und das (ii) bezüglich des genannten DNA-Moleküls nicht degeneriert ist und das (iii) nicht das oben gezeigte DNA-Molekül ist.

- 35 2. Rekombinantes DNA-Molekül nach Anspruch 1, wobei die DNA für das humane Androgen-Rezeptor-Protein codiert, dessen Aminosäuresequenz in Figur 4 gezeigt ist.
3. Klonierungsvektor mit einem DNA-Molekül, das bei der Expression in einem Wirt ein humanes Polypeptid erzeugt, wobei das Polypeptid im wesentlichen die gleiche biologische Aktivität wie das humane Androgen-Rezeptor-Protein aufweist, dessen Aminosäuresequenz in Figur 4 gezeigt ist, oder das für die vollständige Aminosäuresequenz von Figur 4 codiert, wobei das DNA-Molekül (i) unter stringenten Bedingungen nicht mit einem DNA-Molekül hybridisiert, das für das folgende Polypeptid codiert
- 40

1: GGGCCGACCTTCCCGGCTTAAAGAGCTGCTCCCTACCTTAAAGACATCTGAGCGAGGCGAGCAGCACTGCAATCTCTTACGACACACGAGCAGCAGCAGTATCCAGACAGCAGCA  
 2: GGGCCGACCTTCCCGGCTTAAAGAGCTGCTCCCTACCTTAAAGACATCTGAGCGAGGCGAGCAGCACTGCAATCTCTTACGACACACGAGCAGCAGCAGTATCCAGACAGCAGCA  
 3: GGGCCGACCTTCCCGGCTTAAAGAGCTGCTCCCTACCTTAAAGACATCTGAGCGAGGCGAGCAGCACTGCAATCTCTTACGACACACGAGCAGCAGCAGTATCCAGACAGCAGCA  
 4: GGGCCGACCTTCCCGGCTTAAAGAGCTGCTCCCTACCTTAAAGACATCTGAGCGAGGCGAGCAGCACTGCAATCTCTTACGACACACGAGCAGCAGCAGTATCCAGACAGCAGCA  
 5: GGGCCGACCTTCCCGGCTTAAAGAGCTGCTCCCTACCTTAAAGACATCTGAGCGAGGCGAGCAGCACTGCAATCTCTTACGACACACGAGCAGCAGCAGTATCCAGACAGCAGCA  
 6: GGGCCGACCTTCCCGGCTTAAAGAGCTGCTCCCTACCTTAAAGACATCTGAGCGAGGCGAGCAGCACTGCAATCTCTTACGACACACGAGCAGCAGCAGTATCCAGACAGCAGCA  
 7: GGGCCGACCTTCCCGGCTTAAAGAGCTGCTCCCTACCTTAAAGACATCTGAGCGAGGCGAGCAGCACTGCAATCTCTTACGACACACGAGCAGCAGCAGTATCCAGACAGCAGCA  
 8: GGGCCGACCTTCCCGGCTTAAAGAGCTGCTCCCTACCTTAAAGACATCTGAGCGAGGCGAGCAGCACTGCAATCTCTTACGACACACGAGCAGCAGCAGTATCCAGACAGCAGCA  
 9: GGGCCGACCTTCCCGGCTTAAAGAGCTGCTCCCTACCTTAAAGACATCTGAGCGAGGCGAGCAGCACTGCAATCTCTTACGACACACGAGCAGCAGCAGTATCCAGACAGCAGCA  
 10: GGGCCGACCTTCCCGGCTTAAAGAGCTGCTCCCTACCTTAAAGACATCTGAGCGAGGCGAGCAGCACTGCAATCTCTTACGACACACGAGCAGCAGCAGTATCCAGACAGCAGCA  
 11: GGGCCGACCTTCCCGGCTTAAAGAGCTGCTCCCTACCTTAAAGACATCTGAGCGAGGCGAGCAGCACTGCAATCTCTTACGACACACGAGCAGCAGCAGTATCCAGACAGCAGCA  
 12: GGGCCGACCTTCCCGGCTTAAAGAGCTGCTCCCTACCTTAAAGACATCTGAGCGAGGCGAGCAGCACTGCAATCTCTTACGACACACGAGCAGCAGCAGTATCCAGACAGCAGCA  
 13: GGGCCGACCTTCCCGGCTTAAAGAGCTGCTCCCTACCTTAAAGACATCTGAGCGAGGCGAGCAGCACTGCAATCTCTTACGACACACGAGCAGCAGCAGTATCCAGACAGCAGCA  
 14: GGGCCGACCTTCCCGGCTTAAAGAGCTGCTCCCTACCTTAAAGACATCTGAGCGAGGCGAGCAGCACTGCAATCTCTTACGACACACGAGCAGCAGCAGTATCCAGACAGCAGCA  
 15: GGGCCGACCTTCCCGGCTTAAAGAGCTGCTCCCTACCTTAAAGACATCTGAGCGAGGCGAGCAGCACTGCAATCTCTTACGACACACGAGCAGCAGCAGTATCCAGACAGCAGCA  
 16: GGGCCGACCTTCCCGGCTTAAAGAGCTGCTCCCTACCTTAAAGACATCTGAGCGAGGCGAGCAGCACTGCAATCTCTTACGACACACGAGCAGCAGCAGTATCCAGACAGCAGCA  
 17: GGGCCGACCTTCCCGGCTTAAAGAGCTGCTCCCTACCTTAAAGACATCTGAGCGAGGCGAGCAGCACTGCAATCTCTTACGACACACGAGCAGCAGCAGTATCCAGACAGCAGCA  
 18: GGGCCGACCTTCCCGGCTTAAAGAGCTGCTCCCTACCTTAAAGACATCTGAGCGAGGCGAGCAGCACTGCAATCTCTTACGACACACGAGCAGCAGCAGTATCCAGACAGCAGCA  
 19: GGGCCGACCTTCCCGGCTTAAAGAGCTGCTCCCTACCTTAAAGACATCTGAGCGAGGCGAGCAGCACTGCAATCTCTTACGACACACGAGCAGCAGCAGTATCCAGACAGCAGCA  
 20: GGGCCGACCTTCCCGGCTTAAAGAGCTGCTCCCTACCTTAAAGACATCTGAGCGAGGCGAGCAGCACTGCAATCTCTTACGACACACGAGCAGCAGCAGTATCCAGACAGCAGCA  
 21: GGGCCGACCTTCCCGGCTTAAAGAGCTGCTCCCTACCTTAAAGACATCTGAGCGAGGCGAGCAGCACTGCAATCTCTTACGACACACGAGCAGCAGCAGTATCCAGACAGCAGCA  
 22: GGGCCGACCTTCCCGGCTTAAAGAGCTGCTCCCTACCTTAAAGACATCTGAGCGAGGCGAGCAGCACTGCAATCTCTTACGACACACGAGCAGCAGCAGTATCCAGACAGCAGCA  
 23: GGGCCGACCTTCCCGGCTTAAAGAGCTGCTCCCTACCTTAAAGACATCTGAGCGAGGCGAGCAGCACTGCAATCTCTTACGACACACGAGCAGCAGCAGTATCCAGACAGCAGCA  
 24: GGGCCGACCTTCCCGGCTTAAAGAGCTGCTCCCTACCTTAAAGACATCTGAGCGAGGCGAGCAGCACTGCAATCTCTTACGACACACGAGCAGCAGCAGTATCCAGACAGCAGCA  
 25: GGGCCGACCTTCCCGGCTTAAAGAGCTGCTCCCTACCTTAAAGACATCTGAGCGAGGCGAGCAGCACTGCAATCTCTTACGACACACGAGCAGCAGCAGTATCCAGACAGCAGCA  
 26: GGGCCGACCTTCCCGGCTTAAAGAGCTGCTCCCTACCTTAAAGACATCTGAGCGAGGCGAGCAGCACTGCAATCTCTTACGACACACGAGCAGCAGCAGTATCCAGACAGCAGCA  
 27: GGGCCGACCTTCCCGGCTTAAAGAGCTGCTCCCTACCTTAAAGACATCTGAGCGAGGCGAGCAGCACTGCAATCTCTTACGACACACGAGCAGCAGCAGTATCCAGACAGCAGCA  
 28: GGGCCGACCTTCCCGGCTTAAAGAGCTGCTCCCTACCTTAAAGACATCTGAGCGAGGCGAGCAGCACTGCAATCTCTTACGACACACGAGCAGCAGCAGTATCCAGACAGCAGCA  
 29: GGGCCGACCTTCCCGGCTTAAAGAGCTGCTCCCTACCTTAAAGACATCTGAGCGAGGCGAGCAGCACTGCAATCTCTTACGACACACGAGCAGCAGCAGTATCCAGACAGCAGCA  
 30: GGGCCGACCTTCCCGGCTTAAAGAGCTGCTCCCTACCTTAAAGACATCTGAGCGAGGCGAGCAGCACTGCAATCTCTTACGACACACGAGCAGCAGCAGTATCCAGACAGCAGCA  
 31: GGGCCGACCTTCCCGGCTTAAAGAGCTGCTCCCTACCTTAAAGACATCTGAGCGAGGCGAGCAGCACTGCAATCTCTTACGACACACGAGCAGCAGCAGTATCCAGACAGCAGCA  
 32: GGGCCGACCTTCCCGGCTTAAAGAGCTGCTCCCTACCTTAAAGACATCTGAGCGAGGCGAGCAGCACTGCAATCTCTTACGACACACGAGCAGCAGCAGTATCCAGACAGCAGCA  
 33: GGGCCGACCTTCCCGGCTTAAAGAGCTGCTCCCTACCTTAAAGACATCTGAGCGAGGCGAGCAGCACTGCAATCTCTTACGACACACGAGCAGCAGCAGTATCCAGACAGCAGCA  
 34: GGGCCGACCTTCCCGGCTTAAAGAGCTGCTCCCTACCTTAAAGACATCTGAGCGAGGCGAGCAGCACTGCAATCTCTTACGACACACGAGCAGCAGCAGTATCCAGACAGCAGCA  
 35: GGGCCGACCTTCCCGGCTTAAAGAGCTGCTCCCTACCTTAAAGACATCTGAGCGAGGCGAGCAGCACTGCAATCTCTTACGACACACGAGCAGCAGCAGTATCCAGACAGCAGCA  
 36: GGGCCGACCTTCCCGGCTTAAAGAGCTGCTCCCTACCTTAAAGACATCTGAGCGAGGCGAGCAGCACTGCAATCTCTTACGACACACGAGCAGCAGCAGTATCCAGACAGCAGCA  
 37: GGGCCGACCTTCCCGGCTTAAAGAGCTGCTCCCTACCTTAAAGACATCTGAGCGAGGCGAGCAGCACTGCAATCTCTTACGACACACGAGCAGCAGCAGTATCCAGACAGCAGCA  
 38: GGGCCGACCTTCCCGGCTTAAAGAGCTGCTCCCTACCTTAAAGACATCTGAGCGAGGCGAGCAGCACTGCAATCTCTTACGACACACGAGCAGCAGCAGTATCCAGACAGCAGCA  
 39: GGGCCGACCTTCCCGGCTTAAAGAGCTGCTCCCTACCTTAAAGACATCTGAGCGAGGCGAGCAGCACTGCAATCTCTTACGACACACGAGCAGCAGCAGTATCCAGACAGCAGCA  
 40: GGGCCGACCTTCCCGGCTTAAAGAGCTGCTCCCTACCTTAAAGACATCTGAGCGAGGCGAGCAGCACTGCAATCTCTTACGACACACGAGCAGCAGCAGTATCCAGACAGCAGCA  
 41: GGGCCGACCTTCCCGGCTTAAAGAGCTGCTCCCTACCTTAAAGACATCTGAGCGAGGCGAGCAGCACTGCAATCTCTTACGACACACGAGCAGCAGCAGTATCCAGACAGCAGCA  
 42: GGGCCGACCTTCCCGGCTTAAAGAGCTGCTCCCTACCTTAAAGACATCTGAGCGAGGCGAGCAGCACTGCAATCTCTTACGACACACGAGCAGCAGCAGTATCCAGACAGCAGCA  
 43: GGGCCGACCTTCCCGGCTTAAAGAGCTGCTCCCTACCTTAAAGACATCTGAGCGAGGCGAGCAGCACTGCAATCTCTTACGACACACGAGCAGCAGCAGTATCCAGACAGCAGCA  
 44: GGGCCGACCTTCCCGGCTTAAAGAGCTGCTCCCTACCTTAAAGACATCTGAGCGAGGCGAGCAGCACTGCAATCTCTTACGACACACGAGCAGCAGCAGTATCCAGACAGCAGCA  
 45: GGGCCGACCTTCCCGGCTTAAAGAGCTGCTCCCTACCTTAAAGACATCTGAGCGAGGCGAGCAGCACTGCAATCTCTTACGACACACGAGCAGCAGCAGTATCCAGACAGCAGCA  
 46: GGGCCGACCTTCCCGGCTTAAAGAGCTGCTCCCTACCTTAAAGACATCTGAGCGAGGCGAGCAGCACTGCAATCTCTTACGACACACGAGCAGCAGCAGTATCCAGACAGCAGCA  
 47: GGGCCGACCTTCCCGGCTTAAAGAGCTGCTCCCTACCTTAAAGACATCTGAGCGAGGCGAGCAGCACTGCAATCTCTTACGACACACGAGCAGCAGCAGTATCCAGACAGCAGCA  
 48: GGGCCGACCTTCCCGGCTTAAAGAGCTGCTCCCTACCTTAAAGACATCTGAGCGAGGCGAGCAGCACTGCAATCTCTTACGACACACGAGCAGCAGCAGTATCCAGACAGCAGCA  
 49: GGGCCGACCTTCCCGGCTTAAAGAGCTGCTCCCTACCTTAAAGACATCTGAGCGAGGCGAGCAGCACTGCAATCTCTTACGACACACGAGCAGCAGCAGTATCCAGACAGCAGCA  
 50: GGGCCGACCTTCCCGGCTTAAAGAGCTGCTCCCTACCTTAAAGACATCTGAGCGAGGCGAGCAGCACTGCAATCTCTTACGACACACGAGCAGCAGCAGTATCCAGACAGCAGCA  
 51: GGGCCGACCTTCCCGGCTTAAAGAGCTGCTCCCTACCTTAAAGACATCTGAGCGAGGCGAGCAGCACTGCAATCTCTTACGACACACGAGCAGCAGCAGTATCCAGACAGCAGCA  
 52: GGGCCGACCTTCCCGGCTTAAAGAGCTGCTCCCTACCTTAAAGACATCTGAGCGAGGCGAGCAGCACTGCAATCTCTTACGACACACGAGCAGCAGCAGTATCCAGACAGCAGCA  
 53: GGGCCGACCTTCCCGGCTTAAAGAGCTGCTCCCTACCTTAAAGACATCTGAGCGAGGCGAGCAGCACTGCAATCTCTTACGACACACGAGCAGCAGCAGTATCCAGACAGCAGCA  
 54: GGGCCGACCTTCCCGGCTTAAAGAGCTGCTCCCTACCTTAAAGACATCTGAGCGAGGCGAGCAGCACTGCAATCTCTTACGACACACGAGCAGCAGCAGTATCCAGACAGCAGCA  
 55: GGGCCGACCTTCCCGGCTTAAAGAGCTGCTCCCTACCTTAAAGACATCTGAGCGAGGCGAGCAGCACTGCAATCTCTTACGACACACGAGCAGCAGCAGTATCCAGACAGCAGCA

und (ii) bezüglich des genannten DNA-Moleküls nicht degeneriert ist und (iii) nicht das oben gezeigte DNA-Molekül ist.

4. Klonierungsvektor von Anspruch 3, bei dem das DNA-Molekül für das humane Androgen-Rezeptor-Protein codiert, dessen Aminosäuresequenz in Figur 4 gezeigt ist.
5. Verfahren zur Herstellung eines Androgen-Rezeptor-Proteins, wobei das Verfahren die Transfektion oder Transformation eines Wirtsorganismus mit dem Klonierungsvektor nach Anspruch 3 sowie die Reinigung des Androgen-Rezeptor-Proteins, das durch Translation der für das Protein codierenden DNA-Sequenz hergestellt wurde, umfaßt.
6. Verfahren zur Herstellung eines humanen Androgen-Rezeptor-Proteins, wobei das Verfahren die Transfektion oder Transformation eines Wirtsorganismus mit dem Klonierungsvektor nach Anspruch 4 sowie die Reinigung des humanen Androgen-Rezeptor-Proteins, das durch Translation der für das Protein codierenden DNA-Sequenz hergestellt wurde, umfaßt.
7. Verwendung einer Sonde mit komplementären DNA-Sequenzen, die sich von den abgeleiteten Sequenzen ableiten, die für den Androgen-Rezeptor codieren, wie er in Figur 4 gezeigt ist, bei der Herstellung eines Reagens zum Nachweis der Gegenwart von Androgen-Rezeptor-mRNA in Tumorzellen oder zum Nachweis von Anomalien im Androgen-Rezeptor-Gen oder in seiner mRNA, mit der Maßgabe, daß die Sonde (i) unter stringenten Bedingungen nicht mit einem DNA-Molekül hybridisiert, das für das Polypeptid

30

35

40

45

50

55

5 10 15 20 25 30 35

codiert und (iii) bezüglich keines der genannten DNA-Moleküle degeneriert ist und (iv) keines der oben gezeigten DNA-Moleküle ist.

8. Rekombinantes DNA-Molekül mit einer DNA-Sequenz mit dem Strukturgen, das für das humane Androgen-Rezeptor-Protein codiert, dessen Aminosäuresequenz in Figur 4 gezeigt ist.
9. Klonierungsvektor mit einem DNA-Molekül, das bei der Expression in einem Wirt humanes Androgen-Rezeptor-Protein liefert, dessen Aminosäuresequenz in Figur 4 gezeigt ist.
10. Verfahren zur Herstellung eines humanen Androgen-Rezeptor-Proteins, wobei das Verfahren die Transfektion oder die Transformation eines Wirtsorganismus mit dem Klonierungsvektor von Anspruch 9 und die Reinigung des durch Translation der für das Protein codierenden DNA-Sequenz erhaltenen humanen Androgen-Rezeptor-Proteins umfaßt.





[illegible]

et (ii) n'est pas dégénérée avec ladite molécule d'ADN et (iii) n'est pas la molécule d'ADN représentée ci-dessus.

4. Vecteur de clonage de la revendication 3, dans lequel la molécule d'ADN code pour la protéine du récepteur androgénique humain dont la séquence d'acides aminés est représentée sur la figure 4.
5. Procédé de production d'une protéine du récepteur androgénique, le procédé comprenant la transfection ou la transformation d'un organisme hôte avec le vecteur de clonage de la revendication 3, et la purification de la protéine du récepteur androgénique, produite par la traduction de la séquence d'ADN codant pour la protéine.
6. Procédé de production d'une protéine du récepteur androgénique humain, le procédé comprenant la transfection ou la transformation d'un organisme hôte avec le vecteur de clonage de la revendication 4, et la purification de la protéine du récepteur androgénique humain, produite par la traduction de la séquence d'ADN codant pour la protéine.
7. Utilisation d'une sonde comprenant des séquences d'ADN complémentaires dérivées des séquences déduites codant pour le récepteur androgénique comme représenté sur la figure 4, dans la fabrication d'un réactif pour détecter la présence d'ARNm du récepteur androgénique dans des cellules tumorales ou pour détecter des anomalies dans le gène du récepteur androgénique ou dans son ARNm, pourvu que la sonde (i) ne s'hybride pas sous des conditions rigoureuses à une molécule d'ADN qui code pour le polypeptide

[illegible]

et (ii) ne s'hybride pas sous des conditions rigoureuses à une molécule d'ADN qui code pour le polypeptide

45 8. Molécule d'ADN recombinant comprenant une séquence d'ADN possédant le gène de structure qui code pour la protéine du récepteur androgénique humain dont la séquence d'acides aminés est représentée sur la figure 4.

9. Vecteur de clonage comprenant une molécule d'ADN qui lors de l'expression dans un hôte, produit la protéine du récepteur androgénique humain dont la séquence d'acides aminés est représentée sur la figure 4.


50 10. Procédé de production d'une protéine du récepteur androgénique humain, le procédé comprenant la transfection ou la transformation d'un organisme hôte avec le vecteur de clonage de la revendication 9 et la purification de la protéine du récepteur androgénique humain, produite par la traduction de la séquence d'ADN codant pour la protéine.

FIGURE 1 (Page 1 of 2)

A.

Oligo A Complement	3'-ACC	TGT	GAG	GCG	TGT	AAG	GTC	TTC	TTC	AAA	AG-3'	(100%)
hAR (X)	ACA	TGT	GGA	ACC	TGC	AAG	GTC	TTC	TTC	AAA	AG	(84%)
hPR (11)	ACC	TGT	GCG	ACC	TGT	AAG	GTC	TTC	TTC	AAA	AG	(88%)
hMR (4)	ACC	TGT	GCG	ACC	TGC	AAA	GTT	TTC	TTC	AAA	AG	(81%)
hGR (5)	ACT	TGT	GGA	ACC	TGT	AAA	GTT	TTC	TTC	AAA	AG	(81%)
hER (6)	TCC	TGT	GAG	GCC	TGT	AAG	GCC	TTC	TTC	AAA	AG	(91%)
hT3R (3, 17)	ACG	TGT	GAA	GCC	TGC	AAG	GCT	TTC	TTC	AGA	AG	(78%)
hRAR (17)	GCC	TGT	GAG	GCC	TGC	AAG	GCC	TTC	TTC	CGC	CG	(78%)

B.



**DNA-Binding Domain**

	40	50	60+	
BAR	K Q K Y L C A S R N D C I I D K F R R K N C P S C R L R K C Y E A G M	(1004)		
hPR	Q H N Y L C A G R N D C I I V D K I R R K N C P A C R L R K C Q A G M	(714)		
hNR	Q H N Y L C A G R N D C I I D K I R R K N C P A C R L R K C L Q A G M	(714)		
hGR	Q H N Y L C A G R N D C I I D K I R R K N C P A C R L R K C L Q A G M	(714)		
hER	H N D Y M C P A T N Q C C I I D K N R R K S C Q A C R L R K C Y E V G M	(634)		
eVDR	K A M F T C P F M G D C K I I T K D N R R H C Q A C R L R K C V D I G M	(404)		
hT3R	N L H P S Y S C K Y E G C K C V I D K V T R N Q C C Q E C R F K K C I Y V G M	(404)		
VERBA	N L H P T T S C T Y D G C C C V I D K I T R N Q C C Q L C R F K K C I S V G M	(374)		
hBAR	N N M V Y T C H R D K N C I I M K V T R N R C C Q Y C R L Q K C F E V G M	(434)		

**FIGURE 2** (Page 1 of 2)




FIGURE 2 (Page 2 of 2)





FIG. 3

## COMPILED CLONE MAP OF THE HUMAN ANDROGEN RECEPTOR





[illegible]

[illegible]

**FIGURE 4**

[illegible]





830 840 850 860  
 AAAAAATCCCATCTCTGCTCAAGGCGCTTCTACCAAGCTCACCAGAGAGCTATTCGAAGAGAGCTGCAATCAATTCACATTTTGACCCGTGCTAAATCAAGTCCCATATG 3600  
 LysAsnProThrSerCysSerArgArgPheTyrGlnLeuThrLysLeuLeuAspSerValGlnProIleAlaArgGluLeuHisGlnPheThrPheAspLeuLeuIleLysSerHisMet 3650  
 870 880 890 900  
 GTGAGCGGTGGACTTTCCCTGAAATGATGGCAGAGATCATCTCTGTGCAAGTGGCCCAAGATCCCTTCTTGGGAAAGTCAAGCCCATCTATTTCCACACACAGATGAAGATTTGGAAACCCCTAAT 3700  
 ValSerValAspPheProGluMetMetAtaGluIleIleSerValGlnValProLysIleLeuSerGlyLysValLysProIleTyrPheHisThrGlnEnd  
 ACCCAAAACCCACCTTGTCCCTTTTCAGATGTCCTTCGCTGTTATATAACTCTGCACACTACTCTCTGCATTCGCTTGGGGGAAATCCCTCTACTGATGTACAGCTCTGCATGAACATGT 3840  
 TCCCAAGTCTATTTCCCTGGGCTTTTCCCTCTTCTTTCTCTCTGCTCTTTTACCTGCCATGGACATTTTGAATCCGCGTGGCGTGTGGGCTCTCTGCCCTGTGTTTGTAGT 3960  
 TTTGTGTATTTCTTCAAGTCTGATGATCTTCTTGTGGCCCAAGTCAACTGTGCTGTGTTATAGCATGTGCTGTGTGCGCAACCAAGCAAAATGTTTACTCACCTTTATGGCATGGCAA 4080  
 GTTTAGAGAGCTATTAAGTATCTTTGGGAGAGAAACACACAGAGAGATTAATAAAACCC(A)<sub>45</sub>

FIGURE 6



This Page Blank (uspto)



**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

☒ **BLACK BORDERS**

☒ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**

☒ **FADED TEXT OR DRAWING**

☒ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**

☒ **SKEWED/SLANTED IMAGES**

☒ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**

☐ **GRAY SCALE DOCUMENTS**

☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**

☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**

☐ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**

**This Page Blank (uspto)**